Layla Zulfa
By Nicole Lou, Senior Staff Writer, MedPage Today
October 23, 2026
For nearly a decade, the stroke community has operated within a well-defined paradigm: Endovascular therapy (EVT)—the mechanical removal of a blood clot—is the gold standard for large vessel occlusion (LVO) strokes, but its utility has been strictly tethered to a 24-hour window from the time a patient was last known to be well. However, the publication of two landmark Chinese clinical trials in the New England Journal of Medicine suggests that the era of rigid time-based eligibility is rapidly drawing to a close.
The MILD-MT and LATE-MT trials, both conducted at major Chinese stroke centers, represent a significant pivot in neurological intervention. By testing the boundaries of EVT in patients with milder symptoms and those presenting well beyond the standard one-day cutoff, researchers are providing compelling, albeit nuanced, evidence that aggressive intervention can salvage brain function in populations previously deemed "too stable" or "too late" for mechanical thrombectomy.
The Clinical Landscape: Main Facts and Trial Objectives
The standard of care for acute ischemic stroke (AIS) underwent a revolution in 2015, when multiple randomized controlled trials confirmed that mechanical thrombectomy significantly improved outcomes for patients with anterior circulation LVO. Since then, clinical guidelines have gradually expanded these boundaries to include patients with larger ischemic cores and basilar artery occlusions.
The two new trials, led by researchers at Changhai Hospital and the Naval Medical University in Shanghai, aim to address two of the most persistent "gray areas" in stroke neurology:
- MILD-MT (Mild Ischemic Stroke): This trial investigated whether patients with minor strokes—who are often treated with medication alone due to the perceived risk-benefit ratio of invasive surgery—would benefit from the mechanical removal of clots.
- LATE-MT (Delayed Presentation): This study explored the efficacy of EVT for patients presenting between 24 and 72 hours after symptom onset, provided that imaging confirms the presence of "salvageable" brain tissue (penumbra).
Both trials utilized an open-label, multicenter design, randomizing participants to receive either standard medical management alone or medical management supplemented by EVT.
A Chronology of Evidence: From Guidelines to Innovation
The history of stroke intervention is a story of narrowing the clock. For years, the "time is brain" mantra limited treatment to a narrow window. As imaging technology improved, the field shifted from "time-based" models to "tissue-based" models, focusing on whether brain tissue was still viable rather than simply looking at a clock.
- 2015: Landmark trials establish EVT as the definitive treatment for LVO within 6 hours.
- 2018: Guidelines expand the window to 24 hours based on imaging evidence of salvageable tissue.
- 2024: American stroke guidelines broaden eligibility to include patients with larger ischemic cores and basilar artery occlusions.
- October 2026: MILD-MT and LATE-MT are published, signaling a push into the "beyond 24-hour" and "mild-symptom" categories.
The MILD-MT trial, involving 304 participants across 26 centers, found that EVT significantly increased the odds of a patient achieving a modified Rankin scale (mRS) score of 0 or 1—indicating minimal or no disability—at 90 days. The success rate was 69.4% in the EVT group compared to 50.0% in the medical management group (OR 2.32).
Simultaneously, the LATE-MT trial, involving 336 patients across 35 centers, demonstrated that even in the 24-to-72-hour window, the mechanical removal of clots resulted in better functional outcomes (common OR 1.74) compared to conservative medical management.
Supporting Data: Deep Dive into the Results
The MILD-MT Cohort
In the MILD-MT study, patients were selected based on the presence of substantial at-risk tissue on perfusion imaging. The cohort, with a median age in the mid-60s, showed a clear advantage for those receiving EVT. Notably, the trial observed a significant reduction in 7-day neurologic deterioration: 13.9% in the EVT arm versus 31.4% in the control arm. This challenges the common assumption that patients with mild initial symptoms are inherently "safe" and do not require intervention.
However, the researchers noted procedural complications. While symptomatic intracranial hemorrhage (ICH) was comparable between groups, serious procedural issues occurred in 13.2% of the EVT group, including arterial dissection and subarachnoid hemorrhage.
The LATE-MT Cohort
LATE-MT focused on a more complex patient population. With a median time to randomization of 38.5 hours, the investigators found that patients who underwent EVT had better functional recovery. Yet, the safety signals were more pronounced here. Symptomatic ICH occurred in 4.8% of the EVT group compared to 0% in the control group. Furthermore, 90-day mortality was 6.0% in the EVT group versus 1.8% in the medical management group.
Official Responses and Expert Analysis
In an accompanying editorial in the New England Journal of Medicine, Dr. Gaultier Marnat of Bordeaux University Hospital praised the trials as "important advances." He emphasized that the safety incidents in LATE-MT, while concerning, must be viewed through the lens of trial management.
"This finding indicates a need for caution when administering antithrombotic therapies in patients being considered for late endovascular therapy," Dr. Marnat noted. He pointed out that some patients in the LATE-MT study had received IV thrombolysis and aggressive anticoagulation, which may have contributed to the higher rates of hemorrhage. He cautioned that the data might not perfectly translate to non-Asian populations, where the etiology of strokes—often cardioembolic—differs from the intracranial atherosclerotic disease more commonly seen in Asian cohorts.
Despite these caveats, Dr. Marnat concluded that the net benefit-risk ratio for EVT in LVO cases remains firmly in favor of the procedure. The reduction in neurologic deterioration is, in his view, a "clinically meaningful" outcome that cannot be ignored.
Implications: The Future of Stroke Treatment
The findings from China suggest that we are entering an era of personalized stroke care, where the rigid "24-hour rule" is being replaced by sophisticated perfusion imaging that guides clinicians on a case-by-case basis.
1. Re-evaluating "Mild" Strokes
The success of MILD-MT suggests that the current classification of "mild" stroke may be misleading. Even if a patient has a low NIH Stroke Scale score at admission, the presence of an LVO poses a persistent, high-risk threat of sudden, catastrophic neurological decline. EVT may become the standard for these patients to prevent that secondary "worsening."
2. Extending the Window
LATE-MT provides a pathway for patients who present late—perhaps because they live in remote areas or were unaware of their symptoms—to receive life-altering care. However, the trial highlights the need for extreme caution regarding post-procedural antithrombotic therapy.
3. The Need for Global Validation
While these results are robust, the international stroke community is already looking toward ongoing trials like the MOSTE and SELECT LATE studies in France and the United States. These trials will be critical in determining whether the results seen in China are generalizable across different genetic, ethnic, and healthcare delivery landscapes.
Conclusion
The takeaway from MILD-MT and LATE-MT is not that EVT is a risk-free panacea, but rather that the window of opportunity for saving brain tissue is wider than we once believed. By carefully selecting patients through perfusion imaging and refining the safety protocols for late-stage interventions, clinicians may soon be able to significantly reduce the long-term disability burden for thousands of patients worldwide. As the field moves forward, the focus will likely shift from who is eligible for surgery to how we can make those surgeries safer for the patients who need them most.
Nila Kartika Wati
Neng Nana
